We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Complete Blood Count Predicts Asymptomatic Preterm Birth

By LabMedica International staff writers
Posted on 08 Apr 2020
Print article
Image: The XN-350 hematology analyzer and blood cell counter (Photograph courtesy of Sysmex).
Image: The XN-350 hematology analyzer and blood cell counter (Photograph courtesy of Sysmex).
Preterm birth (PTB), defined as birth before 37 complete weeks of gestation, is a very serious obstetric problem worldwide. It affects 5% to 18% of all deliveries in the world and represents an enormous health care burden.

One of the most simple, economic, and routine clinical tests during pregnancy is the complete blood count (CBC). CBC and its derived parameters, including neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR), have been recognized as inflammatory markers for low‐grade inflammatory diseases in recent years.

Medical Laboratory Scientists at the Fujian Medical University (Fuzhou, China) and their colleagues included in a retrospective case‐control study, 15,387 total pregnant women for preterm deliveries and term deliveries between January and December 2017. After adjusting for these four clinical features with propensity score‐matched (PSM) analysis, a total of 105 and 210 pregnant women were retained in the study group and control group, respectively.

A Sysmex blood cell counter (Kobe, Japan) was used as a blood cell counting machine. The CBC parameters used in the study were as follows: WBC, white blood cell; Neu#, neutrophil count; Lym#, lymphocyte count; Mon#, monocyte count; HGB, hemoglobin; HCT, hematocrit; RDW, red cell distribution width; PLT, platelet count; MPV, mean platelet volume; PCT, plateletcrit; PDW, platelet distribution width; NLR, neutrophil‐to‐lymphocyte ratio; LMR, lymphocyte‐to‐monocyte ratio; PLR, platelet‐to‐lymphocyte ratio.

The team reported that NLR, MLR, PLR, PDW, and lymphocytes were statistically different between the two groups before PSM analysis. After PSM analysis, the statistical differences between the first four indicators (NLR, MLR, PLR, and PDW) were even more statistically significant, in addition, HGB and MPV, HCT also reached statistical differences between the two groups after PSM analysis. The mean values of NLR, PDW, MPV, HGB, HCT, PLR were significantly higher, and LMR and lymphocytes were significantly lower in preterm delivery group after PSM analysis.

The authors concluded that the combined marker of CBC parameters can supplement other markers to predict PTB about 10 weeks in advance. This combined marker had a very high negative predictive value for PTB. Therefore, in subjects with normal combined marker value, further screening tests for PTB may be eliminated unless clinical suspicion is high. The study was published on march 27, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Fujian Medical University
Sysmex


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.